Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,105 Cr
verified against source
Revenue YoY
14%
reported change
EBITDA
₹314 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Ajanta Pharma reported a strong Q3 FY24 with consolidated revenue of INR 1,105 crore, up 14% YoY, driven by broad-based growth across branded generics. EBITDA margin held steady at 28%, supported by improved gross margins and lower logistics costs. PAT surged to INR 210 crore from INR 135 crore a year ago. The India business grew 5% (9M: 11%), outpacing IPM by 200 bps, while Asia branded grew 28% (aided by spillover) and Africa institutional jumped 179%. US generics declined 5% due to a high base from last year's flu season. Management guided for FY24 EBITDA margin of 27% ±1%, factoring in Red Sea freight headwinds and higher Q4 expenses. Key risks include US price erosion and unpredictable institutional business. Overall, the company is well-positioned with a strong balance sheet, consistent cash generation, and a disciplined capital allocation policy.
Colored figures show movement against the previous available record.
Guidance to track
- Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
- India business expected to grow 12-13% for full year FY24, with Q4 aspiration to cross 15%.
- Asia branded business expected to grow low double digits for full year FY24.
- Africa branded business expected to grow mid to high single digits for full year FY24.
Risks flagged
- Freight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.
- While current price erosion is stable at high single digits, any acceleration could impact US generics profitability and overall margins.
- Institutional business is lumpy and dependent on agency funding and malaria season, making it difficult to forecast.
- Cardiology growth was lower than IPM due to price revision in a major product in December 2022, and competitive intensity has increased.
Key quotes
- Our performance has been excellent on the back of increased volumes, price increase, and new product launches.
- We are revising our full year guidance to 27% ±1% for full year financial year 2024.
- We are always on the lookout for suitable brand acquisition targets and also opportunities.
Research modules